Business Context and Reporting Period
Company: TherapeuticsMD, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: July 17, 2017
Business Context: The filing discloses a regulatory update regarding the Company's investigational drug TX-004HR, an applicator-free estradiol vaginal softgel capsule intended to treat moderate-to-severe vaginal pain during sexual intercourse (dyspareunia) associated with vulvar and vaginal atrophy (VVA) due to menopause.
Key Financial Metrics
This Form 8-K is a regulatory disclosure and does not contain financial statements. The filing text does not provide values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The material event reported is the issuance of a press release on July 17, 2017, providing a regulatory update on the New Drug Application (NDA) for TX-004HR. No financial changes or operational metrics were disclosed in this specific filing.
Guidance, Outlook, and Risks
Management Commentary: The Company issued a press release (Exhibit 99.1) detailing the status of the NDA for TX-004HR.
Legal Disclaimer: The information in Items 7.01 and 9.01, including the press release, is furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934. It is not subject to the liabilities of that section and shall not be incorporated by reference into any other filings under the Securities Act or Exchange Act.
Investor Verification Checklist
- Review the full text of the press release (Exhibit 99.1) to understand the specific details of the TX-004HR regulatory update.
- Verify the current status of the NDA for TX-004HR through FDA databases or subsequent company announcements.
- Consult the Company's most recent 10-K or 10-Q filings for financial performance data, as this 8-K contains no financial metrics.